What Is an Antitussive? How It Works, Types, and Uses

An antitussive is any drug or substance designed to suppress the urge to cough. The term comes from the Latin “tussis” (cough) with the prefix “anti,” and it covers everything from the dextromethorphan in a grocery-store cough syrup to prescription codeine to newer drugs still working through clinical trials. Antitussives work by interrupting the cough reflex at different points along the chain, and the specific point of interruption is what separates the major types from one another. The evidence behind them is more complicated than the pharmacy aisle suggests.

Why the Body Coughs in the First Place

Coughing is a protective reflex. Sensory nerve endings in your airways detect irritants, mucus, inhaled particles, or acid, and they fire signals along the vagus nerve to the brainstem. The brainstem’s “cough center” processes those signals and sends a motor command back out to the muscles of your chest, diaphragm, and throat, which coordinate the explosive burst of air that clears whatever triggered the alarm.

This reflex exists to protect your lungs from aspiration and infection, and it likely evolved specifically to prevent stomach contents or foreign particles from reaching deep lung tissue.² That protective role is why suppressing a cough is not always a good idea, a point worth keeping in mind as we get into how these drugs work.

Centrally Acting Antitussives

The best-known antitussives work in the brain. They dampen the cough center’s response to incoming signals, so even though the irritation in your airways is still there, your brainstem is less likely to trigger the cough motor sequence. The two you will encounter most often are codeine and dextromethorphan (usually listed as “DXM” or “DM” on product labels).

Codeine is an opioid, and its cough-suppressing effect comes mainly from activating the mu-opioid receptor in the central nervous system, with some contribution from the kappa-opioid receptor.³ Because it is an opioid, codeine carries risks of sedation, constipation, respiratory depression, and dependence. Your body converts codeine into morphine via the liver enzyme CYP2D6, and people who are “ultrarapid metabolizers” of that enzyme can end up with dangerously high morphine levels from a standard dose. A typical 30-milligram dose of codeine can produce roughly 4 milligrams of morphine in such individuals.⁴ Codeine is prescription-only in most countries, though some places still sell low-dose formulations over the counter.

Dextromethorphan is the non-opioid alternative found in dozens of over-the-counter cold and cough products. It also acts centrally but does not bind opioid receptors in the same way codeine does, so it carries far less risk of respiratory depression or physical dependence at normal doses. It is processed through the same CYP2D6 enzyme pathway, however, which matters for drug interactions.

Peripherally Acting Antitussives

Rather than quieting the brain’s cough center, peripherally acting antitussives interrupt the signal before it gets there. They work at the level of the airway nerves themselves, either numbing the sensory endings or modulating the chemical signals those nerves use to communicate.

Benzonatate is the most widely prescribed peripheral antitussive in the United States. It is structurally related to local anesthetics and works by inhibiting voltage-gated sodium channels in the stretch receptors of the lungs and airways, essentially numbing them so they stop sending cough-triggering signals.⁵ It comes as a soft gelatin capsule that must be swallowed whole; chewing or dissolving it can numb the mouth and throat, and in young children, even a single capsule can be fatal.

Levodropropizine is another peripheral antitussive, more common in Europe and parts of Asia than in the U.S. It appears to work by modulating sensory neuropeptides in the respiratory tract. Animal studies showed that levodropropizine failed to suppress cough in animals whose sensory neuropeptides had been depleted, while codeine worked regardless, which supports the idea that levodropropizine’s mechanism is genuinely peripheral and neuropeptide-dependent.⁶ Clinical guidelines from the American College of Chest Physicians have noted that peripherally acting drugs like levodropropizine showed a higher level of benefit for cough related to bronchitis than central agents like codeine and dextromethorphan.⁷

How Well Do Over-the-Counter Cough Suppressants Actually Work?

This is where the story gets uncomfortable. The evidence for OTC cough medicines treating acute cough, the kind you get with a cold or bronchitis, is weak. A systematic review in the BMJ found conflicting evidence on the effectiveness of antitussives compared with placebo, and even when individual trials showed a statistically meaningful result, the actual effect sizes were small and of “doubtful clinical relevance.”⁸

A Cochrane review reached a similar conclusion: in adults, six trials comparing antitussives to placebo gave variable results, and in children, antitussives were no more effective than placebo. The review’s bottom line was that there is “no good evidence for or against the effectiveness of OTC medicines in acute cough.”⁹ A meta-analysis of studies on dextromethorphan and codeine in adults found these central antitussives were only marginally better than placebo.⁷

Part of the problem is that acute cough from a cold resolves on its own within a week or two regardless of treatment, so any study has to tease apart the drug’s effect from natural recovery and the placebo response. The placebo response in cough trials is substantial, which makes it hard for active drugs to demonstrate a meaningful edge. A review in ERJ Open Research discussed how antitussive effects in clinical trials involve pharmacological, psychological, and nonspecific components, all layered together.¹⁰ None of this means cough medicines do nothing for every person, but it does mean the confident claims on product packaging outrun the clinical evidence.

Honey, Menthol, and Other Non-Drug Approaches

Given the underwhelming evidence for OTC antitussives, non-drug options deserve a serious look, especially for children. A well-known trial in children found that honey was significantly better than no treatment at reducing cough frequency and improving combined symptom scores.¹¹ Honey should never be given to infants under one year old because of the risk of botulism, but for older children and adults, a spoonful before bed is a reasonable first step.

Menthol, the compound responsible for the cooling sensation in cough drops and chest rubs, has a real physiological basis for suppressing cough. In guinea pig experiments, menthol vapor delivered to the upper airways suppressed cough triggered from the lower airways, working through the cold-sensitive TRPM8 receptor on nasal trigeminal nerve fibers. The effect came specifically from stimulating the nose, not the trachea, and was mimicked by cold air but not by menthol’s inactive mirror-image molecule.¹² Additional studies confirmed that both menthol isomers applied to the nose significantly reduced cough parameters.¹³ The takeaway: menthol’s cough relief is not just a placebo comfort. It involves a genuine neural reflex originating in the nose that dials down the cough response lower in the airways.

Safety Risks That Get Overlooked

Antitussives are so common that people often treat them as harmless. They are not, and the risks differ sharply by drug.

Codeine

Beyond the ultrarapid-metabolizer risk already mentioned, codeine carries a measurably increased risk of death in people over 85 and in patients with respiratory disease. A case-control study found that codeine-exposed patients over 85 had roughly two and a half times the risk of death compared to unexposed patients of the same age, and those with respiratory disease had about a 29% increase in risk.¹⁴ In people with chronic obstructive pulmonary disease (COPD) or other conditions that already compromise breathing, suppressing the cough reflex with an opioid can tip the balance toward dangerous mucus retention or respiratory depression.¹⁵ Chronic codeine use also builds physical dependence, and withdrawal symptoms can include drug craving and irritability.⁴

Dextromethorphan

DXM is safe at recommended doses for most people, but it has become a drug of abuse, particularly among teenagers, because high doses produce dissociative effects. At supra-therapeutic doses, especially in combination with selective serotonin reuptake inhibitors (SSRIs), dextromethorphan can trigger serotonin syndrome, a potentially life-threatening condition involving agitation, elevated body temperature, and muscle rigidity.¹⁶ Case reports document hospitalizations from overdoses of commonly available OTC cough medicines containing DXM.¹⁷

Benzonatate

Benzonatate is especially dangerous in small children. Because of its local-anesthetic properties, a child who chews or sucks on a capsule can develop rapid-onset seizures, cardiac arrhythmias, and death. Both fatal unintentional ingestions in children under five and fatal intentional ingestions in older adolescents have been documented.¹⁸ The FDA added warnings to benzonatate’s label about the increased risk of death in children under ten.¹⁹ If you have benzonatate prescribed to you and children are in the household, storing it out of reach is not a casual suggestion.

Why Antitussives Are Not Recommended for Young Children

In January 2008, the FDA issued a public health advisory recommending that OTC cough and cold medicines not be used in infants and children under two, because of the risk of serious and potentially life-threatening side effects.²⁰ Since then, most manufacturers have voluntarily relabeled their products to say “do not use” in children under four, and many pediatricians extend that recommendation to children under six. The Cochrane review found that antitussives were no more effective than placebo in children across multiple trials, so the risk-benefit calculation simply does not favor giving these drugs to young kids.⁹ For children over one year old, honey remains the best-supported alternative.

When You Should Not Suppress a Cough

Because coughing clears mucus and debris from the airways, suppressing it is counterproductive in several situations. If you have a “productive” cough, one that is bringing up phlegm, silencing it with an antitussive can allow mucus to pool in the lungs and increase the risk of infection. This is especially true for people with COPD, bronchiectasis, or cystic fibrosis, where mucus clearance is already impaired. An antitussive in those settings can make things worse, not better.

The general principle: antitussives make the most sense for dry, non-productive coughs that are disrupting sleep, conversation, or daily life and have no identifiable treatable cause. When a cough is doing useful work, the goal should be to treat whatever is triggering it rather than muting the symptom.

Drug Interactions Worth Knowing About

Dextromethorphan is metabolized by two liver enzyme pathways: CYP2D6 (which converts it to dextrorphan) and the CYP3A family (which converts it to 3-methoxymorphinan).²¹ Any drug that inhibits those enzymes can raise DXM levels in your blood. CYP3A inhibitors like erythromycin and even grapefruit juice have been shown to alter the metabolism ratios. A phase 1 trial of the antifungal isavuconazole found that co-administration increased dextromethorphan exposure by about 18%.²² An 18% bump on its own is modest, but stacking multiple interacting drugs, or combining DXM with an SSRI, compounds the risk toward serotonin syndrome.

The practical lesson: if you take antidepressants, antifungals, or certain antibiotics, mention it before taking any cough suppressant, even an OTC one. Pharmacists are generally better at catching these interactions than the label on the box.

Chronic Cough and the Limits of Traditional Antitussives

Acute cough from a cold resolves within a few weeks. Chronic cough, loosely defined as a cough lasting more than eight weeks, is a different animal. It can stem from postnasal drip, asthma, acid reflux, or sometimes no identifiable cause at all, a category doctors call “refractory” or “unexplained” chronic cough. Traditional antitussives like DXM and codeine are generally not effective for chronic cough and were not designed for long-term use.

For refractory chronic cough, clinicians have increasingly turned to repurposed drugs from other fields. Gabapentin and pregabalin, originally developed for nerve pain and seizures, have been shown to reduce cough frequency and improve quality of life in chronic cough patients.²³ Speech pathology techniques, which teach patients to control the urge-to-cough sensation and retrain breathing patterns, are also used alongside or instead of medication. A systematic review and meta-analysis found that medical therapy (including neuromodulating drugs, tricyclic antidepressants, and others), speech therapy, and procedural interventions are all part of the toolkit for neurogenic cough.²⁴

A New Class of Antitussive on the Horizon

The biggest development in antitussive pharmacology in decades is the arrival of P2X3 receptor antagonists, a class of drugs that target a completely different part of the cough signaling chain. The P2X3 receptor sits on sensory nerve endings in the airways and responds to ATP, a molecule released by damaged or irritated cells. Blocking that receptor reduces the hypersensitivity that keeps chronic cough patients coughing long after any obvious trigger has resolved.

Gefapixant is the first drug in this class to reach phase 3 trials. Two large randomized controlled trials (COUGH-1 and COUGH-2) showed that gefapixant at 45 mg twice daily significantly reduced 24-hour cough frequency compared with placebo, with reductions of about 18.5% in COUGH-1 at 12 weeks and about 14.6% in COUGH-2 at 24 weeks.²⁵ A dose-response meta-analysis confirmed these findings but characterized the effects as small, with moderate certainty of evidence. The tradeoff: roughly 32 extra patients per 100 experienced taste-related side effects compared to placebo, ranging from altered taste to outright loss of taste.²⁶

A broader meta-analysis of 11 randomized controlled trials of P2X3 antagonists as a class found significant reductions in 24-hour cough frequency and improvements in cough-specific quality of life.²⁷ These drugs are not miracle cures. The cough reductions are modest, and taste disturbance is a real quality-of-life issue for many patients. But for a condition that previously had no approved targeted therapy, even a modest, mechanism-based option represents progress. Several other P2X3 antagonists are in the pipeline, and some aim to be more selective for the P2X3 receptor to reduce the taste side effects that plagued gefapixant.

The lower dose of gefapixant, 15 mg twice daily, did not show significant cough reduction in either of the phase 3 trials, which underscores a tricky therapeutic window: the dose that works is also the dose most likely to alter your sense of taste.²⁵ For patients who have been coughing nonstop for months or years, that tradeoff may be worth it. For someone with a two-week cold, it obviously is not. The field is clearly moving toward treating chronic cough as its own distinct condition with its own pharmacology, rather than just handing patients the same OTC syrups that struggle to outperform placebo in the first place.

1
PubMed Central. Anatomy and neuro-pathophysiology of the cough reflex arc
2
PubMed Central. Perspective on the human cough reflex
3
PubMed Central. Central and peripheral mechanisms of narcotic antitussives: codeine-sensitive and -resistant coughs
4
Scientific Reports. Nationwide study of chronic codeine use and its impact on cough related diseases in South Korea
5
Neuropharmacology. Benzonatate inhibition of voltage-gated sodium currents
6
Pulmonary Pharmacology. Peripheral site of action of levodropropizine in experimentally-induced cough: Role of sensory neuropeptides
7
PubMed Central. Cough management: a practical approach
8
PubMed Central. Systematic review of randomised controlled trials of over the counter cough medicines for acute cough in adults
9
PubMed Central. Over-the-counter (OTC) medications for acute cough in children and adults in ambulatory settings
10
PubMed Central. Decoding the impact of the placebo response in clinical trials for chronic cough
11
JAMA Pediatrics. Effect of Honey, Dextromethorphan, and No Treatment on Nocturnal Cough and Sleep Quality for Coughing Children and Their Parents
12
PubMed Central. The role of trigeminal nasal TRPM8-expressing afferent neurons in the antitussive effects of menthol
13
PubMed Central. Modulation of cough response by sensory inputs from the nose – role of trigeminal TRPA1 versus TRPM8 channels
14
PubMed Central. Increased risk of death with codeine use in the elderly over 85 years old and patients with respiratory disease: A case-control study using retrospective insurance claims database
15
PubMed. Management of respiratory problems in the aged
16
PubMed. Dextromethorphan-induced serotonin syndrome
17
PubMed Central. Serotonin syndrome after an overdose of over-the-counter medicine containing dextromethorphan
18
Pediatrics. Benzonatate Exposure Trends and Adverse Events
19
PubMed Central. Benzonatate toxicity in a teenager resulting in coma, seizures, and severe metabolic acidosis
20
PubMed Central. Physician and Parent Response to the FDA Advisory About Use of Over the Counter Cough and Cold Medications
21
Journal of Chromatography B: Biomedical Sciences and Applications. Dextromethorphan as an in vivo probe for the simultaneous determination of CYP2D6 and CYP3A activity
22
PubMed Central. Pharmacokinetic Effects of Isavuconazole Coadministration with the Cytochrome P450 Enzyme Substrates Bupropion, Repaglinide, Caffeine, Dextromethorphan, and Methadone in Healthy Subjects
23
PubMed Central. An update and systematic review on drug therapies for the treatment of refractory chronic cough
24
PubMed Central. Curbing the Cough: Multimodal Treatments for Neurogenic Cough: A Systematic Review and Meta-Analysis
25
The Lancet. Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: randomised, double-blind, controlled, parallel-group, phase 3 trials (COUGH-1 and COUGH-2)
26
PubMed Central. Efficacy and Tolerability of Gefapixant for Treatment of Refractory or Unexplained Chronic Cough A Systematic Review and Dose-Response Meta-Analysis
27
PubMed. Safety and efficacy of P2X3 receptor antagonist for the treatment of refractory or unexplained chronic cough: A systematic review and meta-analysis of 11 randomized controlled trials